ACADIA Pharmaceuticals Inc. Share Price Today: Live Updates & Key Insights
ACADIA Pharmaceuticals Inc. share price today is $29, up 2.67%. The stock opened at $28.655 against the previous close of $28.45, with an intraday high of $29.28 and low of $28.23.
ACADIA Pharmaceuticals Inc. Share Price Chart
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. Share Price Performance
ACADIA Pharmaceuticals Inc. Institutional Holdings
ACADIA Pharmaceuticals Inc. Market Status
ACADIA Pharmaceuticals Inc. Fundamentals
Market Cap 4902.09 M
PB Ratio 3.5521
PE Ratio 12.9318
Enterprise Value 3632.63 M
Total Assets 1564.20 M
Volume 1782723
ACADIA Pharmaceuticals Inc. Company Financials
About ACADIA Pharmaceuticals Inc. & investment objective
Company Information ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Organisation Biotechnology
Employees 796
Industry Biotechnology
CEO Ms. Catherine E. Owen Adams
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
ACADIA Pharmaceuticals Inc. FAQs
What is the share price of ACADIA Pharmaceuticals Inc. today?
The current share price of ACADIA Pharmaceuticals Inc. is $29.
Can I buy ACADIA Pharmaceuticals Inc. shares in India?
Yes, Indian investors can buy ACADIA Pharmaceuticals Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy ACADIA Pharmaceuticals Inc. shares in India?
You can easily invest in ACADIA Pharmaceuticals Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy ACADIA Pharmaceuticals Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of ACADIA Pharmaceuticals Inc..
Can I buy fractional shares of ACADIA Pharmaceuticals Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. has a market cap of $4902.09 M.
In which sector does ACADIA Pharmaceuticals Inc. belong?
ACADIA Pharmaceuticals Inc. operates in the Biotechnology sector.
What documents are required to invest in ACADIA Pharmaceuticals Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of ACADIA Pharmaceuticals Inc.?
The PE ratio of ACADIA Pharmaceuticals Inc. is 12.93 and the PB ratio is 3.55.